Abstracts Archive - Page 120 of 1683 - ATC Abstracts

2022 American Transplant Congress
Circulating Galectin-3 Levels Increase in Syngeneic Rat Recipients of Vascularized Composite Allografts Subjected to Prolonged Ischemia
Z. Wang¹, B. Li¹, Y. Wang¹, D. Yoeli¹, N. Nakra¹, N. Limon De La Rosa¹, A. A. Su¹, A. Jani¹, D. W. Mathes¹, K. M. Washington¹, E. Farkash², C. A. Huang¹
¹University of Colorado, Denver | Anschutz Medical Campus, Aurora, CO, ²University of Michigan, Ann Arbor, Ann Arbor, MI
*Purpose: During the process of transplantation, organs and tissue are necessarily subjected to some degree of hypoxic and ischemic injury during procurement, preservation and following…
2022 American Transplant Congress
Six-Month Outcomes Among Lung Transplant Patients with COVID-19
L. D. Mahan, J. Rose, M. Mohanka, A. Banga
UT Southwestern Medical Center, Dallas, TX
*Purpose: There is limited data on the outcomes beyond the acute illness among lung transplant (LT) patients with Coronavirus disease 2019 (COVID-19). The current study…
2022 American Transplant Congress
Risk of Post-Transplant Lymphoproliferative Disease After Anti-Thymocyte Globulin in Childhood Solid-Organ Transplant Recipients
A. M. McKay¹, C. Teoh¹, J. Vasilevska-Ristovka², J. Browne², T. Banh², A. Dipchand¹, V. Ng¹, M. Solomon¹, U. Allen¹, Y. Avitzur¹, R. Parekh³
¹Transplant & Regenerative Medicine Centre, The Hospital for Sick Children, Toronto, ON, Canada, ²Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ³Division of Nephrology, Department of Medicine, Women’s College Hospital and University Health Network, Toronto, ON, Canada
*Purpose: Determine if the use of anti-thymocyte globulin (ATG) in pediatric solid organ transplant recipients was associated with an increased risk of post-transplant lymphoproliferative disorder…
2022 American Transplant Congress
Longevity Matching for Living Donor Renal Transplantation
S. Karhadkar¹, J. Dawes¹, K. Wirshup¹, J. Kolansky¹, A. Gregor¹, A. Diamond², A. DiCarlo¹
¹Temple University Hospital, Philadelphia, PA, ²-, Garnet Valley, PA
*Purpose: Living donor kidney transplantation (LDKT) continues to become a more prevalent treatment method for ESRD and is known to increase both organ availability and…
2022 American Transplant Congress
Organs from Donors with Positive SARS-CoV-2 NAT+ Testing: A Report from the Ad Hoc Disease Transmission Advisory Committee
L. Danziger-Isakov¹, J. D. Goldman¹, A. Wooley¹, S. Pouch¹, A. Agarwal¹, G. Berry¹, K. Dunn¹, S. Ho¹, M. Kittleson¹, D. H. Lee¹, D. Levine¹, C. Marboe¹, G. Marklin¹, R. Razonable¹, S. Taimur¹, H. Te¹, C. Fox², C. Jett², S. Booker², D. Klassen², R. LaHoz¹
¹OPTN, Richmond, VA, ²UNOS, Richmond, VA
*Purpose: Decision to transplant organs from SARS-CoV-2 NAT+ donors(N+D) balances risk of donor-derived infection with the scarcity of available organs to meet the needs of…
2022 American Transplant Congress
“ABO-Adjusted CPRA”: A Unified Metric for Immunologic Compatibility in Kidney Transplantation
L. Gragert¹, M. Kadatz², J. Alcorn³, D. Stewart³, D. Chang², J. Gill², R. Liwski⁴, H. Gebel⁵, E. Kransdorf⁶, J. Gill², J. Lan²
¹Tulane University, New Orleans, LA, ²University of British Columbia, Vancouver, BC, Canada, ³UNOS, Richmond, VA, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Emory University, Atlanta, GA, ⁶Cedars-Sinai, Beverly Hills, CA
*Purpose: Implementation of the kidney allocation system in 2014 greatly reduced access disparity due to HLA sensitization. To address persistent disparities among both candidate cPRA…
2022 American Transplant Congress
En-Bloc Kidney Transplantation in Children Over a 33-year Period in USA – A Comparative Study
P. Gogalniceanu¹, I. D. Kostakis², P. Chandak³, G. Papadakis⁴, J. Stojanovic⁵, F. Calder⁴, I. Loukopoulos⁴, N. Kessaris⁴
¹Abdominal Transplant Surgery, Guy's Hospital, London, London, United Kingdom, ²Department of HPB Surgery and Liver Transplantation, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, United Kingdom, ³Transplantation, Guy's and St Thomas Hospitals NHS Trust and King's College London, London, United Kingdom, ⁴Guy's Hospital, London, United Kingdom, ⁵Great Ormond Street Hospital, London, United Kingdom
*Purpose: En-bloc kidney transplantation is not commonly performed due to scarcity of such organs as well as due to potential technical and thrombotic problems. We…
2022 American Transplant Congress
Post-Kidney Transplant Valacyclovir versus Valganciclovir for CMV Prophylaxis: A Randomized Controlled Trial
P. S. Verghese¹, A. Matas², S. Chinnakotla², M. Evans³, H. Balfour Jr⁴
¹Univ of Minnesota Pediatric Nephrology, Minneapolis, MN, ²Surgery, University of Minnesota Medical School, Minneapolis, MN, ³Biostatistics, University of Minnesota, Minneapolis, MN, ⁴Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN
*Purpose: Valganciclovir (valG) is an effective CMV prophylactic agent post-kidney transplant (KTx) with significant side effects. Valacyclovir (valA) may be effective for CMV prophylaxis with…
2022 American Transplant Congress
EBV+ PTLD Tumor MicroRNAs Detected in Circulating Extracellular Vesicles Are Decreased in Pediatric Transplant Recipients with EBV+ PTLD
A. Sen¹, J. Enriquez¹, M. Rao¹, M. Glass¹, Y. Balachandran¹, S. Syed¹, C. Twist¹, K. Weinberg¹, S. D. Boyd¹, D. Bernstein¹, A. Trickey¹, D. Gratzinger¹, B. Tan¹, M. G. Lapasaran¹, M. A. Robien², M. Brown³, B. Armstrong⁴, M. Sever⁴, D. Desai⁵, G. Mazariegos⁶, C. Chin⁷, T. Fishbein⁸, R. S. Venick⁹, A. Tekin¹⁰, H. Zimmermann¹¹, R. U. Trappe¹², C. O. Esquivel¹, O. M. Martinez¹, S. M. Krams¹
¹Stanford U, Palo Alto, CA, ²NIH, Bethesda, MD, ³NIAID, Bethesda, MD, ⁴Rho, Durham, NC, ⁵UT Southwestern, Dallas, TX, ⁶Pittsburgh U, Pittsburgh, PA, ⁷CCHMC, Cincinnati, OH, ⁸Georgetown U, Washington, DC, ⁹UCLA, LA, CA, ¹⁰Miami U, Miami, FL, ¹¹DIAKO Ev. Diakonie-Krankenhaus, Bremen, Germany, ¹²Charité - Universitätsmedizin, Berlin, Germany
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation. Predisposing factors for PTLD include primary Epstein-Barr virus (EBV) infection in children,…
2022 American Transplant Congress
Role of Circulating Tumour Cells in the Management of the Liver Transplant Patient with Hepatocellular Carcinoma
F. Villalba¹, F. Alconchel², L. Sáenz³, M. Sánchez-Lorencio¹, D. Ferreras², P. Cascales², F. Sánchez-Bueno², R. Robles², P. Ramírez²
¹IMIB-Virgen de la Arrixaca, Murcia, Spain, ²Surgery and Organ Transplantation, Virgen de la Arrixaca University Hospital (IMIB-Virgen de la Arrixaca), Murcia, Spain, ³Rafael Méndez Hospital, Lorca, Spain
*Purpose: For hepatocellular carcinoma (HCC), liver transplantation (LT) is considered a curative treatment, however, more than 10% of transplant recipients have recurrences within the first…